source
- Alnylam to launch larger study of RNA therapy for Huntington’s diseaseAlnylam Therapeutics announced it will expand its clinical program for an RNA‑based drug aimed at treating Huntington’s disease. The decision comes amid a challenging landscape for neurodegenerati…
- Bristol Myers Squibb identifies cause of safety signal in lupus CAR‑T trialBristol Myers Squibb's cell therapy division is confronting ongoing safety challenges with its autoimmune CAR‑T program. The company says it has pinpointed the underlying cause of the safety signa…